AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2021
Jan 5, 2021
31523_dirs_2021-01-05_36d4e326-d44c-4fd0-abcf-f92324c36a2e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-12-31
Reporting Person: Campbell Bradley L (Director, Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Common Stock | F | 7617 | $23.09 | Disposed | 347215 | Direct |
| 2021-01-02 | Common Stock | F | 26908 | $23.09 | Disposed | 320307 | Direct |
| 2021-01-03 | Common Stock | F | 13974 | $23.09 | Disposed | 306333 | Direct |
| 2021-01-04 | Common Stock | M | 10514 | $6.45 | Acquired | 316847 | Direct |
| 2021-01-04 | Common Stock | S | 10514 | $22.1728 | Disposed | 306333 | Direct |
| 2021-01-04 | Common Stock | A | 57620 | — | Acquired | 363953 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-04 | Stock Options (right to buy) | $6.45 | M | 10514 | Disposed | 2022-02-15 | Common Stock (10514) | Direct |
| 2021-01-04 | Stock Options (right to buy) | $21.78 | A | 92792 | Acquired | 2031-01-04 | Common Stock (92792) | Direct |
Footnotes
F1: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $21.58 to $23.14 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
F4: The Restricted Stock Units will vest in four equal annual installments beginning on January 4, 2022.
F5: All of the options were fully vested and exercisable as of the transaction date.
F6: These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.